CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 156 enrolled
Drug / intervention
rituximab +5 morebiological
Likely dose
rituximab 375 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00544219
NCT00544219N/ACompleted
CompareCT.gov

Prospective Evaluation of the Predictive Value of PET in Patients With Diffuse Large B-cell-lymphoma Under R-CHOP-14. A Multicenter Study

Swiss Cancer Institute·interventional·Posted Oct 16, 2007·Updated May 15, 2019

In Brief

A clinical study evaluating rituximab, cyclophosphamide, and 4 other interventions for Lymphoma. Completed, enrolled 156 participants across 19 sites in 2 countries.

Detailed Summary

RATIONALE: Studying PET scans given to patients with cancer who are undergoing treatment may help doctors predict how patients will respond to treatment. PURPOSE: This clinical trial is studying PET scans in patients with diffuse large B-cell lymphoma who are receiving rituximab together with cyclophosphamide, doxorubicin, vincristine, and prednisone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesItaly, Switzerland
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 16, 2007
Enrollment StartSep 1, 2007
Primary CompletionSep 1, 2012
Study CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 18.7 years ago

Interventions

rituximabbiological

375 mg/m2 i.v. per cycle

cyclophosphamidedrug

750 mg/m2 i.v. per cycle

doxorubicin hydrochloridedrug

50 mg/m2 i.v. per cycle

prednisonedrug

100 mg/day p.o. per cycle

vincristine sulfatedrug

1.4 mg/m2 (max. 2.0 mg) i.v. per cycle

positron emission tomographyprocedure

PET Scan during treatment